Cost Utility of Switching From Trivalent to Quadrivalent Influenza Vaccine in Turkey.

Creative Commons License

Amiche A., Tanriover M. D., Bellier L., Ugur B., Akin L.

Value in health regional issues, vol.25, pp.15-22, 2021 (ESCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 25
  • Publication Date: 2021
  • Doi Number: 10.1016/j.vhri.2020.11.006
  • Journal Name: Value in health regional issues
  • Journal Indexes: Emerging Sources Citation Index (ESCI), Scopus, ASSIA, EMBASE, MEDLINE
  • Page Numbers: pp.15-22
  • Keywords: cost, cost utility, economic analysis, incremental cost-effectiveness ratio, influenza, influenza B virus, public health impact, seasonal influenza, Turkey, vaccination, vaccine, PUBLIC-HEALTH IMPACT, SEASONAL INFLUENZA, SURVEILLANCE, PRODUCTIVITY, STATES
  • Hacettepe University Affiliated: Yes


Objectives: Trivalent influenza vaccines (TIVs) are widely used but protect against only 1 of the 2 co-circulating influenza B virus lineages. Quadrivalent influenza vaccines (QIVs) include a B strain from each lineage to overcome mismatches. The main objective of this study was to determine the cost-utility and budget impact of switching from vaccination with TIV to QIV in the population recommended for influenza vaccination in Turkey.